Genitourinary Cancers | Specialty

The OncLive Genitourinary Cancer condition center page is a comprehensive resource for clinical news and expert insights across genitourinary (GU) malignancies, including renal cell carcinoma, urothelial carcinoma, and prostate cancer. This section features news articles, interviews in written and video format, and podcasts that focus on the evolving treatment paradigm of GU cancers and emerging research.

TKI/Immunotherapy Combos Lead Advances in mRCC, But Questions Remain

March 11th 2020

Chung-Han (Joe) Lee, MD, PhD, discussed advancements in metastatic renal cell carcinoma regarding combination regimens and ongoing questions of how to treat patients upon disease progression.

Dr. Tsao on Rationale for Staging Renal Cell Carcinoma

March 10th 2020

Che-Kai Tsao, MD, discusses the rationale behind staging disease, especially in the context of when patients are diagnosed with renal cell carcinoma.

Adjuvant Chemotherapy Shows Strong Benefit in Upper Tract Urothelial Carcinoma

March 7th 2020

Adjuvant platinum-based chemotherapy reduced the risk of disease recurrence or death by 55% in patients with upper tract urothelial carcinoma, according to findings from the phase III POUT trial that have now been published in The Lancet.

Durvalumab/Tremelimumab Combo Misses OS Endpoints in Metastatic Bladder Cancer

March 6th 2020

Durvalumab alone did not improve overall survival compared with standard-of-care chemotherapy in patients with unresectable urothelial cancer whose tumors had high levels (≥25%) of PD-L1 expression, missing both primary endpoints of the phase III DANUBE trial.

Dr. McDermott on VEGF/PD-1 Inhibition in RCC

March 5th 2020

David F. McDermott, MD, discusses the research behind combining VEGF inhibitors with PD-1/PD-L1 inhibitors in renal cell carcinoma treatment.

Rapid Advances Change the Paradigm in Bladder Cancer

March 4th 2020

Arjun V. Balar, MD, discusses how immunotherapy options are helping to reduce reliance on platinum chemotherapy and cystectomy, as well as further efforts to engage the immune system in the fight against bladder cancer and other pathways toward greater treatment efficacy and quality of life for patients.

Dr. Lee on Treatment Options mRCC

March 4th 2020

Chung-Han Lee, MD, PhD, discusses treatment options for patients with metastatic renal cell carcinoma.

Dr. Figlin on Novel Combinations in Kidney Cancer Treatment

March 2nd 2020

Robert A. Figlin, MD, discusses novel combinations in the treatment of patients with kidney cancer.

Dr. McGregor on Combos With Nivolumab, Cabozantinib, and Sunitinib in RCC

February 29th 2020

Bradley McGregor, MD, discusses combination therapies with nivolumab, cabozantinib, and sunitinib in renal cell carcinoma.

Dr. Powles on the Mission of the Uromigos Twitter Group

February 29th 2020

Thomas Powles, MD, MBBS, MRCP, discusses the mission and goals for the Uromigos Twitter group.

First-in-Class ADC Expands Portfolio of Precision Therapies in Bladder Cancer

February 28th 2020

Bradley McGregor, MD, discusses enfortumab vedotin-ejfv’s path to approval and its future potential in bladder cancer.

Dr. Joshi on Durvalumab/RT Combo in Locally Advanced Urothelial Cancer

February 28th 2020

Monika Joshi, MD, discusses durvalumab (Imfinzi) and radiation therapy (DUART) in locally advanced urothelial cancer of the bladder.

Despite Setback, Expert Sees Novel Immunotherapy Combos on Horizon in mRCC

February 21st 2020

Martin H. Voss, MD, discusses the phase I/II trial evaluating MEDI0680 plus durvalumab in metastatic renal cell carcinoma and what similar research efforts lie ahead.

FDA Grants Breakthrough Designation to Frontline Enfortumab Vedotin/Pembrolizumab in Bladder Cancer

February 20th 2020

The FDA has granted a breakthrough therapy designation to the combination of enfortumab vedotin-ejfv and pembrolizumab as a first-line treatment of patients with unresectable locally advanced or metastatic urothelial cancer who are unable to receive cisplatin-based chemotherapy.

Dr. Bakouny on the Role of Cytoreductive Nephrectomy in mRCC

February 19th 2020

Ziad Bakouny, MD, MSc, discusses the role of cytoreductive nephrectomy in metastatic renal cell carcinoma.

Dr. Vaishampayan on Systemic Therapy Followed by Cytoreductive Nephrectomy in mRCC

February 18th 2020

Ulka Vaishampayan, MD, discusses the considerations when giving patients with metastatic renal cell carcinoma systemic therapy followed by cytoreductive nephrectomy.

Breaking Ground in GU Cancers

February 17th 2020

Daniel P. Petrylak, MD, discusses important new developments in bladder and prostate cancer.

Dr. Choueiri on Phase I/II Data of MK-6482 in Advanced Clear Cell RCC

February 15th 2020

Toni K. Choueiri, MD, director, Lank Center for Genitourinary Oncology, director, Kidney Cancer Center, senior physician, Dana-Farber Cancer Institute, and Jerome and Nancy Kohlberg Chair and professor of medicine, Harvard Medical School, discusses phase I/II results of a trial evaluating the oral HIF-2 α inhibitor MK-6482 in patients with advanced clear cell renal cell carcinoma.

Dr. Alva on the Shift Toward Combination Therapy in mRCC

February 15th 2020

Ajjai Shivaram Alva, MBBS, discusses the shift toward combination therapy versus monotherapy in metastatic renal cell carcinoma.

Dr. Figlin on the Evolving Treatment Landscape of Renal Cell Carcinoma

February 15th 2020

Robert A. Figlin, MD, discusses the evolving treatment landscape of renal cell carcinoma (RCC).